

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25  
NOTIFICATION OF LATE FILING

SEC FILE NUMBER  
000-32877

(Check One) ☒ Form 10-K and Form 10-KSB ☐ Form 20-F  
☐ Form 11-K ☐ Form 10-Q and Form 10-QSB ☐ Form N-SAR  
For Period Ended: December 31, 2001

CUSIP NUMBER  
74267T109

☐ Transition Report on Form 10-K  
☐ Transition Report on Form 20-F  
☐ Transition Report on Form 11-K  
☐ Transition Report on Form 10-Q  
☐ Transition Report on Form N-SAR  
For the Transition Period Ended: \_\_\_\_\_

Read Instructions (on back page) Before Preparing Form. Please Print or Type.  
Nothing in this form shall be construed to imply that the Commission has  
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify  
the Item(s) to which the notification relates:

N/A

PART I - REGISTRANT INFORMATION

Pro-Pharmaceuticals, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

189 Wells Avenue, Suite 200

Address of Principal Executive Office (Street and Number)

Newton, Massachusetts 02459

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense  
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should  
be completed. (Check box if appropriate)

- ☒ (a) The reasons described in reasonable detail in  
Part III of this form could not be eliminated  
without unreasonable effort or expense;
- ☒ (b) The subject annual report, semi-annual report,  
transition report on Form 10-K, Form 10-KSB,  
Form 20-F, Form 11-K or Form N-SAR, or portion  
thereof, will be filed on or before the  
fifteenth calendar day following the prescribed  
due date; or the subject quarterly report or  
transition report on Form 10-Q, Form 10-QSB, or  
portion thereof, will be filed on or before the  
fifth calendar day following the prescribed due  
date; and
- ☐ (c) The accountant's statement or other exhibit  
required by Rule 12b-25(c) has been attached if  
applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB, Form 20-F, Form 11-K, Form 10-Q and Form 10-QSB, Form N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach Extra Sheets if Needed)

The Registrant is unable to file, on the prescribed filing date, without unreasonable effort and expense, its Annual Report on Form 10-KSB for the year ended December 31, 2001, because of unanticipated difficulties and delays in collecting and formatting data.

PART IV - OTHER INFORMATION

- (1) Name and telephone number of persons to contact in regard to this notification

Susan K. Shapiro, Esq.	617	854-4000
-----	-----	-----
(Name)	(Area Code)	(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes | ☐ No
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes | ☐ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Registrant anticipates that there will be significant changes in its results of operations from the corresponding period for the last fiscal year. However, at this time the Registrant is unable to offer any estimates because of unanticipated difficulties in collecting and formatting data.

Pro-Pharmaceuticals, Inc.  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 1, 2002  
-----

By: /s/ David Platt  
-----  
David Platt, Ph.D., President

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.